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Growth rate and associated factors in small abdominal aortic
aneurysms
Vega de Ceniga M, Gomez R, Estallo L, et al. Eur J Vasc Endovasc Surg
2006;31:231-6
Conclusion: Growth rates of small abdominal aortic aneurysms
(AAAs) increase with the baseline size of the aneurysm. Both diabetes and
chronic limb ischemia reduce growth rate of small AAAs.
Summary: This was a longitudinal, observational, prospective study to
evaluate growth rates of small AAAs and factors that may influence growth.
Patients with AAAs 5 cm in diameter were divided into two groups by a
baseline ultrasound examination. Group I patients had aneurysms between 3
and 3.9 cm (n  246), and group II patients had aneurysms between 4 and
4.9 cm (n  106). Patients in group I underwent annual ultrasound scans,
and patients in group II underwent CT scans every 6 months. There were
352 patients (333 men and 19 women) monitored for a mean of 55.2 
37.4 months (range, 6.3 to 199.8 months).
Aneurysm growth rate was greater in patients in group II (4.72 5.93
mm/y vs 2.07  3.23 mm/y; P  0.0001). During follow-up, 87 patients
(24.7%) died. One patient died because of a ruptured AAA and one died
during elective aneurysm repair. Two aneurysms ruptured in group II: one
had expanded to 5.6 cm, and the second had expanded to 6 cm. Rapid
expansion (defined as4mm/y) was more prevalent in group II than group
I (36.8% vs 13.8%; P .0001). No expansion (0mm) was observed in 17.9%
of patients in group II and 25.2% of patients in group I (P .14). During the
follow-up period there were 36 patients (14.6%) in group I where the
aneurysm grew to 5 cm in diameter, and there were 72 patients (67.9%) in
group II where the aneurysm reached 5 cm in diameter (odds ratio 12.35;
95% confidence interval, 7.19 to 21.28; P  .0001).
Cardiovascular risk factors did not influence growth rate in group I.
Diabetic patients in group II had significantly lower growth rates than
nondiabetic patients (1.69  3.51 vs 5.22  6.11 mm/y; P  .032).
Chronic limb ischemia was associated with slower aneurysm expansion (odds
ratio 0.47; 95% confidence interval, 0.22 to 0.99; P  .045).
Comment:There are nomajor surprises here. Small aneurysms rupture
very infrequently, and larger small aneurysms grow faster than smaller small
aneurysms. The differential affects of cardiovascular risk factors on growth
rate of aneurysms, although previously shown, is perhaps not as well appre-
ciated. The UK Small Aneurysm Trial also demonstrated decreased growth
rates of aneurysms in patients with peripheral arterial disease and in patients
with diabetes (Circulation 2004;110:16-21). Observations with respect to
peripheral arterial disease and diabetes on growth rate of small AAAs
observed in this study are therefore unlikely the result of chance. There may
be changes in the collagen vs elastin content of the aortic wall in patients with
diabetes or in those whose atherosclerotic risk factors have produced both
occlusive as well as aneurysmal disease.
Effect of very high-intensity statin therapy on regression of coronary
atherosclerosis: the ASTEROID trial
Missen FE, Nicholls SJ, Sipahi I, et al, and the ASTEROID Investigators.
JAMA 2006;295:1556-65
Conclusion: Very-high-intensity statin therapy with rosuvastatin can
reduce coronary atherosclerosis as assessed by intravascular ultrasound
(IVUS).
Summary: The authors performed a prospective, open-labeled,
blinded end point trial to determine the effect of very-high-intensity statin
therapy on coronary atherosclerosis as assessed by IVUS. The study was
conducted in 53 community and tertiary medical centers in the United
States, Canada, Europe, and Australia. Coronary atheromas were assessed at
baseline and after 24 months of treatment. A total of 507 patients had a
baseline IVUS examination and received at least one 40-mg dose of rosuv-
astatin a day. There was no placebo arm of the trial, with all patients receiving
40mg/d of rosuvastatin. At 24months, 349 patients had an evaluable IVUS
examination. Primary efficacy parameters were a change in atheroma volume
percentage measured by IVUS and change in atheroma volume in a 10-mm
subsegment of artery with the greatest disease severity at baseline. A second
efficacy variable was normalized atheroma volume for the entire artery.
At baseline, the mean low-density lipoprotein cholesterol (LDL) was
130.4 34.3 mg/dL. This declined to 60.8 20.0 mg/dL with treatment
with rosuvastatin, a mean reduction of 53.2% (P  .001). The mean
high-density lipoprotein cholesterol (HDL) level at baseline was 43.1 
11.1 mg/dL. This increased to 49.0  12.6 mg/dL with rosuvastatin
treatment, an increase of 14.7% (P  .001). The mean change in the
percentage of atheroma volume was –0.98%  3.15% with a median of
–0.79% (97.5% confidence interval [CI], –1.21% to –0.53%), P  .001
compared with baseline. The mean change in atheroma volume in the most
diseased 10-mm subsegment was –6.1  10.1 mm3, with a median change
of –5.6 mm3 (97.5% CI, –6.8 mm to –.40 mm3 ), P .001 compared with
baseline. Total atheroma volume showed a 6.8% median reduction, with a
mean reduction of –14.7 25.7mm3 and amedian reduction of –12.5mm3
(95% CI, –15.5 to 10.5 mm3), P  .001 compared with baseline.
Comment: This study demonstrates convincing regression of athero-
sclerosis in the coronary circulation with high-dose statin therapy. The study
has some limitations in that there was no placebo control. Also, 22 patients
were withdrawn because of ischemic events, and those patients may repre-
sent actual progression of atherosclerosis under the treatment protocol.
Nevertheless, in the patients evaluated, coronary atherosclerosis was reduced
with the high-dose statin therapy used in this study. There were minimal
complications and intolerance associated with the drug. It seems clear that
high-dose statin therapy is indicated for patients with significant coronary
disease. There is no evidence to date, however, that such therapy will benefit
patients with cerebrovascular or peripheral arterial disease. Those trials still
need to be done.
Improvement in stroke mortality in Canada and the United States,
1990–2002
Quanhe Y, Botto L, Erickson JD, et al. Circulation 2006;113:1343-53
Conclusion: Stroke mortality has improved in the United States and
Canada during the period of folic acid fortification of grain products. This
suggests high homocysteine levels are independent risk factors for stroke and
can be modified by folic acid fortification of grain products.
Summary: Folic acid fortification of grain products was fully imple-
mented in the United States and Canada by 1998. Theoretically, this should
result in a population-wide reduction in blood homocysteine levels. If it is
assumed high homocysteine levels are an independent risk factor for stroke,
this should result in a decrease in stroke mortality. The authors sought to
address the hypothesis fortification of grain products with folic acid reduces
stroke mortality in the United States and Canada. They used segmented
log-linear regression analysis to evaluate stroke mortality trends before and
after folic acid fortification of grain products. These data were compared
with stroke mortality during the same period in England and Wales, where
fortification of grain products with folic acid was not required.
Average blood homocysteine concentrations decreased and average
blood folate concentrations increased in the United States after fortification.
The previously observed decline in stroke mortality in the United States
from 1990 to 1997 further accelerated from 1998 to 2002 in virtually all
segments of the population. Overall, change varied from –0.3% (95%
confidence interval [CI], –0.7 to 0.08) to –2.9 (95% CI, –3.5 to –2.3) per
year (P  .0005). Sensitivity analysis indicated there were no other major
recognized risk factor changes to account for the decreased trend of stroke-
related deaths in the United States. In Canada, the fall in stroke mortality
averaged –1.0% (95% CI, –1.4 to –0.6) per year from 1990 to 1997. This
accelerated to –5.4% (95% CI, –6.0 to –4.7) per year from 1998 to 2002 (P
 .0001). There was no change in stroke mortality in England and Wales
from 1990 to 2002.
Comment: These data provide indirect evidence that stroke mortality
can be modified by reducing overall homocysteine levels in the population.
The sophisticated statistical methods used in this report make it unlikely that
the findings presented represent chance alone. It is, however, unknown
whether the reduction in stroke mortality is secondary to a decrease inci-
dence of stroke or a decrease in the case fatality rate of stroke, and thus
reflecting better stroke care rather than decreased stroke incidence.
Matrix metalloproteinase-8 and -9 are increased at the site of abdom-
inal aortic aneurysm rupture
Wilson WRW, Anderton M, Schwalbe EC, et al. Circulation 2006;113:
438-45
Conclusion: There is an increase of matrix metalloproteinase-8
(MMP-8) and MMP-9 at the site of aortic aneurysm rupture.
Summary: Processes that lead directly to abdominal aortic aneurysm
(AAA) rupture are not well understood. The authors sought to study the
role of MMPs and their inhibitors (TIMPs) in the cellular and proteolytic
activity of ruptured AAAs. Biopsy specimens were obtained from the ante-
rior wall of the aorta from 20 ruptured and 55 nonruptured AAAs. In 12 of
the ruptured AAAs, biopsy specimens were taken from rupture site and
analyzed for MMP-1, -2, -3, -8, -9, and -13. TIMP-1 and TIMP-2 were all
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also quantified from each biopsy. Analysis was by enzyme-linked immuno-
absorbent assay.
The biopsy specimens of the anterior sites showed no difference in
MMPs or TIMPs concentrations in ruptured vs nonruptured aneurysms.
MMP-8 and MMP-9 levels were elevated from the biopsy specimens of
12 ruptured sites compared with the 12 paired anterior wall biopsy sites
(MMP-8, P .001; MMP-9, P .01). Other MMPs and TIMPs showed
no difference. Expression of MMP-8 and MMP-9 was mediated by native
mesenchymal cells. Expression was independent of inflammatory infil-
trate.
Comment: The article suggests a final common pathway in the break-
down of extra cellular matrix in AAA rupture. The corollary, of course, is that
inhibition of MMP-8 or MMP-9 activity could potentially decrease the risk
of aneurysm rupture. Perhaps someday patients with aortic aneurysms
unsuitable for repair will be treated with inhibitors of MMP-9 or MMP-8 in
an attempt to prevent death from aneurysm rupture.
Asymptomatic central venous stenosis in hemodialysis patients
Levit RD, Cohen RM, Kwak A, et al. Radiology 2006;238:1051-6
Conclusion: In patients with a hemodialysis access graft and an asymp-
tomatic central venous stenosis (CVS) of 50%, treatment of the CVS
results in more rapid stenosis progression compared with a nontreatment
approach.
Summary: The authors evaluated the natural history of 50% asymp-
tomatic CVSs in hemodialysis patients. Outcome of serial treatment of CVS
with percutaneous catheter-based techniques (PTA) was also evaluated. All
patients in this study required maintenance procedures for their dialysis
access.
Between 1998 and 2004, 35 patients (19 men, 16 women), with a
mean age of 58.7 years, were found to have asymptomatic CVS of 50%.
CVS was measured by using venograms obtained before and after PTA.
Patients with arm swelling, multiple CVSs, or indwelling catheters, were
excluded. CVS progression was calculated by comparing degrees of stenoses
with serial venographic examinations.
The mean severity of CVSs before intervention was 71% (range, 50% to
100%), with 62% of lesions having associated collateral vessels. Twenty eight
percent of CVSs were not treated. The mean degree of stenosis in the
untreated group was 72% (range, 30% to 100%). Mean progression of
stenosis in the untreated group was –0.8% point per day. No untreated CVS
progressed to symptoms, stent placement, or developed additional CVS.
PTA was used to treat 62 CVS lesions (72%). The mean degree of
stenosis in the treated group was 74% (range, 50% to 100%) before and 40%
(range, 0% to 75%) after treatment. In the treated group, mean progression
of CVS was 0.21% per day after treatment. Six of the 62 treated CVS lesions
were monitored, with symptomatic escalation of the CVS as manifested by
arm swelling, need for stent placement, or development of additional CVS
lesions.
Comment: Treatment of an asymptomatic CVS in a dialysis patient is
not a good thing. One is reminded of the old adage that it is wise to avoid
poking a skunk. A major weakness of this study is that the patients were
undergoing maintenance procedures for their dialysis access. We do not
know if the CVS contributed to the need for the dialysis access maintenance.
It would be interesting to know if there was a higher rate of repeat
procedures for maintenance of dialysis access in patients with treated vs
untreated CVS.
Balloon angioplasty versus implantation of nitinol stents in the super-
ficial femoral artery
Schillinger M, Sabeti S, Loewe C, et al. N Engl J Med 2006;354:1879-88
Conclusion: At 6 months and 12 months, percutaneous angioplasty of
superficial femoral artery stenoses with primary implantation of a self-
expanding nitinol stent is superior to percutaneous angioplasty of superficial
femoral artery stenoses with optional secondary stenting.
Summary: The authors evaluated whether primary implantation of a
self-expanding nitinol stent in the superficial femoral artery yielded superior
anatomic and clinical benefits compared with a policy of percutaneous
transluminal angioplasty with stenting reserved as a secondary option. The
study screened 252 patients for participation, of which 104 were eligible for
randomization. These patients all had chronic limb ischemia and claudica-
tion due to stenosis or occlusion of the superficial femoral artery. Fifty-one
patients underwent primary stent implantation, and 53 patients underwent
angioplasty with secondary stent implantation.
The primary study end point was a rate of restenosis of at least 50% in
the treated segment 6 months after intervention. Restenosis was determined
by computed tomography angiography or digital subtraction angiography
and was measured in the worst angiographic view of the narrowest stent
segment or in the 10-mm segments proximal and distal to the treated
superficial femoral artery segment. Secondary end points included restenosis
as determined by duplex scanning at 3, 6, and 12months. Rutherford’s stage
of peripheral arterial disease maximal walking capacity on the treadmill at 24
hours and at 3, 6, and 12 months were also determined. Amputation and
death at 6 and 12 months were additional secondary end points. The ankle
brachial index was measured at 24 hours, and at 3, 6, and 12 months.
The mean length of the treated arterial segment was 132  71 mm in
the primary stent group vs 127 55mm in the angioplasty/secondary stent
group. In the secondary stent group, 17 patients (32%) had secondary
stenting. At 6 months, the rate of restenosis on angiography was 43% in the
angioplasty group and 24% in the primary stent group (P  .05). At 12
months, rates of restenosis were 63% in the angioplasty group and 37% in the
primary stent group as determined by duplex scanning (P  .01). No
amputations occurred in either group at 6 or 12 months, and one patient
died in the primary stent group at 12 months. Patients in the stent group
walked farther on the treadmill at 6 months (average distance, 363 vs 270
meters; P  .04) and at 12 months (average distance, 387 vs 267 meters; P
 .04). At 12 months the ankle brachial index was higher in the stent group
than in the angioplasty group (P  .03). The rate of stent fracture was 2%.
Comment: This study suggests that the primary use of nitinol stents
may improve what is a relatively poor result of angioplasty and secondary
stenting of the superficial femoral artery. Given that previous studies have
suggested that an exercise program is as effective as or more effective than
angioplasty of the superficial femoral artery, it is a shame that the authors did
not include a control group in their trial. It would also have been nice to
know whether the increased walking distance measured on the treadmill
translated to an increased quality of life for the patients in this study.
Nevertheless, it can be said that given the end points of this trial, the use of
primary stenting with nitinol stents for angioplasty of the superficial femoral
artery, was superior to selective stenting after angioplasty of the superficial
femoral artery.
Homocysteine lowering with folic acid and B vitamins in vascular
disease
The Heart Outcomes Prevention Evaluation (HOPE) Two Investigators. N
Engl J Med 2006;354:1567-77
Conclusion: In patients with vascular disease, supplemental folic acid,
vitamin B6, and B12 do not reduce the risk of major cardiovascular events.
Summary: In observational studies, higher homocysteine levels have
been associated with increased rates of stroke and heart disease. It is known
vitamins B6, B12, and folate can lower homocysteine levels. The purpose of
this study was to determine whether the risk of major cardiovascular events
in patients with vascular disease could be reduced with the use of supple-
mental vitamin therapy.
Patients who were aged 55 years and who had vascular disease or
diabetes were randomly assigned either treatment with placebo or a combi-
nation of 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin
B12. The study enrolled 5552 patients aged55 years and monitored them
for an average of 5 years. The primary end point was a composite of death
from myocardial infarction, stroke, and other cardiovascular causes.
In the treatment group, mean plasma homocysteine levels decreased by
2.4 m/L (0.3 mg/L). In the placebo group, mean plasma homocysteine
increased by 0.8 m/L (0.1 mg/L). Primary outcome end points occurred
in 18.8% of the active therapy group (n  519), and in 19.9% (n  547) of
the placebo group (relative risk [RR], 0.95; 95% confidence interval [CI],
0.84 to 1.07; P  .41). Compared with placebo, vitamin treatment did not
decrease risk of death from cardiovascular causes (RR, 0.96; 95% CI, 0.81 to
1.13) or myocardial infarction (RR, 0.98; 95% CI, 0.85 to 1.14). More
patients in the treated groupwere hospitalized for unstable angina (RR 1.24;
95% CI, 1.04 to 1.49). There were fewer strokes in the active treatment
group than the placebo group (RR, 0.75; 95% CI, 0.59 to 0.97).
Subgroup analysis indicated no heterogenicity of treatment effect in
patients from regions where food had mandatory supplementation of folate
vs regions where food was not supplemented. There was no difference in
treatment affects in patients with the top third of baseline homocysteine
levels or in the patients with the top fifth of homocysteine levels. With
adjustments for age, sex, and treatment assignment, baseline homocysteine
level as a continuous measure was a predictor of cardiovascular events.
Comment: Multiple trials have now demonstrated a lack of efficacy of
supplemental vitamin therapy to decrease cardiovascular events. This is despite
documented lowering of homocysteine levels by the vitamin therapy. This
discordance between epidemiology and results of clinical trials is similar to that
noted for estrogen and antioxidant vitamins. It may be that the epidemiologic
data of homocysteine are confused by confounding variables that cannot be
completely adjusted for inmultivariable analysis. Itmay, however, simply be that
homocysteine is a marker but not a cause of vascular disease.
Massive pulmonary embolism
Kucher N, Rossi E, DeRosa M, et al. Circulation 2006;113:577-82
Conclusion: Mortality of pulmonary embolism in patients with mas-
sive pulmonary embolism (PE) is not reduced by thrombolysis or embolec-
tomy. There does appear to be reducedmortality in patients with massive PE
who have placement of inferior vena cava filters.
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